4d Molecular Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
4D Molecular Therapeutics announces its 2026 Annual Meeting of Stockholders, scheduled for June 17, 2026, to elect directors, ratify auditor appointment, and vote on executive compensation.
NASDAQ
4D Molecular Therapeutics, Inc. has filed a definitive proxy statement with the SEC.
NASDAQ
4D Molecular Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 17, 2025, to vote on director elections, auditor ratification, executive compensation, and say-on-pay frequency.
NASDAQ
4D Molecular Therapeutics has filed a definitive proxy statement with the Securities and Exchange Commission.
NASDAQ
4D Molecular Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on May 21, 2024, to vote on the election of a director and the ratification of the company's independent accounting firm.